Abstract 4983
Background
Over 90% of mBC pts have hormone receptor positive disease. Until today tam is considered the standard of care. Due to the low incidence of mBC, there is a lack of data regarding its efficacy and safety. No prospectively randomized study in mBC pts has been completed so far. The Male-GBG54 study is the first prospective, randomized, multicenter trial evaluating the efficacy and safety of different endocrine treatment options in male pts with BC.
Methods
In the Male-GBG54 trial (NCT01638247), pts were randomized to receive tam 20mg/day per os (p.o.) in Arm A, tam + GnRHa subcutaneous (s.c.) q3m in Arm B and exemestane 25 mg/day p.o. + GnRHa s.c. in Arm C for 6 months (mo) as (neo)adjuvant or metastatic therapy. Further treatment was conducted as per local guidelines. Primary objective was the estradiol (E2) suppression after 3 mo. Secondary objectives were the E2 suppression after 6 mo and levels of different steroidal hormones after 3 and 6 mo. Quality of life was assessed using validated questionnaires. 14 pts/group were needed for the F-test to have 80% power to detect a difference in estradiol decrease between the groups at the 5% significance level.
Results
Between October 2012 and May 2017, 55 pts were randomized in Germany, of whom 46 pts were fully evaluable and comprised the 6-mo analysis set. The median age was 62 years. Baseline characteristics were well balanced between the 3 arms. The median E2 level with tam increased by 67% after 3 mo and by 41% after 6 mo. In pts receiving tam + GnRH and AI+ GnRH, there was an initial decrease of E2 after 3 mo of 85% and 73% respectively. After 6 mo of therapy the decrease was 59% and 63% respectively. Other hormone parameters will also be presented at the meeting.
Conclusions
This is worldwide the first fully recruited prospective randomized trial, evaluating the impact of 3 different endocrine treatments in male BC. The analysis revealed an increase of E2 levels along the course of therapy after an initial steep decrease when GnRHa was given. The therapy was well tolerated with no safety signals.
Clinical trial identification
Male-GBG54 trial (NCT01638247)
Editorial Acknowledgement
Resources from the same session
4196 - Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase 3b CompLEEment-1 trial
Presenter: Claudio Zamagni
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
4172 - Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
Presenter: Junien Sirieix
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion session - Breast cancer, metastatic - Invited Discussant 293PD, 294PD and 273PD
Presenter: Caroline Schroeder
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Slides
Webcast
5618 - Balixafortide (a novel CXCR4 inhibitor) and Eribulin in HER2-neg Metastatic Breast Cancer (MBC) patients (pts): a Phase I trial
Presenter: Javier Cortes Castan
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
4464 - Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
Presenter: Jennifer Specht
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
1741 - Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients
Presenter: MING-SHEN DAI
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion session - Breast cancer, metastatic - Invited Discussant 285PD, 286PD and 287PD
Presenter: Alessandra Gennari
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Slides
Webcast
2770 - PERNETTA – A non comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207)
Presenter: Jens Huober
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
5383 - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): results from the multicohort phase II FINESSE trial
Presenter: Rina Hui
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion session - Breast cancer, metastatic - Invited Discussant 288PD, 289PD and one LBA TBC
Presenter: Lisa Carey
Session: Poster Discussion session - Breast cancer, metastatic
Resources:
Slides
Webcast